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Development of antiseptic 
adaptation and cross-adapatation 
in selected oral pathogens in vitro
tim Verspecht1, esteban Rodriguez Herrero1, Ladan Khodaparast2,3, Laleh Khodaparast2,3, 
Nico Boon4, Kristel Bernaerts5, Marc Quirynen1,6 & Wim teughels1,6
there is evidence that pathogenic bacteria can adapt to antiseptics upon repeated exposure. More 
alarming is the concomitant increase in antibiotic resistance that has been described for some 
pathogens. Unfortunately, effects of adaptation and cross-adaptation are hardly known for oral 
pathogens, which are very frequently exposed to antiseptics. Therefore, this study aimed to determine 
the in vitro increase in minimum inhibitory concentrations (MICs) in oral pathogens after repeated 
exposure to chlorhexidine or cetylpyridinium chloride, to examine if (cross-)adaptation to antiseptics/
antibiotics occurs, if (cross-)adaptation is reversible and what the potential underlying mechanisms are. 
When the pathogens were exposed to antiseptics, their MICs significantly increased. This increase was 
in general at least partially conserved after regrowth without antiseptics. Some of the adapted species 
also showed cross-adaptation, as shown by increased MICs of antibiotics and the other antiseptic. In 
most antiseptic-adapted bacteria, cell-surface hydrophobicity was increased and mass-spectrometry 
analysis revealed changes in expression of proteins involved in a wide range of functional domains. 
these in vitro data shows the adaptation and cross-adaptation of oral pathogens to antiseptics and 
antibiotics. This was related to changes in cell surface hydrophobicity and in expression of proteins 
involved in membrane transport, virulence, oxidative stress protection and metabolism.
Prevention and treatment of oral diseases such as tooth decay, gingivitis and periodontitis focusses primarily 
on removal of the dental plaque biofilm. The removal of dental plaque is frequently combined with the use of 
antimicrobials in mouth rinses and toothpastes such as chlorhexidine (CHX) and cetylpyridinium chloride 
(CPC)1–3. They are broad-spectrum cationic biocides, which generally affect the microbial membrane integrity 
of both Gram-positive and Gram-negative bacteria4. These antiseptics are also commonly used as co-adjuvants 
in the treatment of periodontal diseases such as gingivitis and chronic and aggressive periodontitis5, as the 
clinical anti-plaque efficacy of CHX and CPC on oral supragingival and subgingival biofilms has been shown 
extensively1,6,7.
Although these antiseptics are considered to be relatively safe, their unspecific mode of action and their 
long-term use via toothpastes and mouth rinses might create undesired and underestimated side effects. It has 
been documented that dead bacteria can stimulate the necrotrophic activity of periodontal pathogens, thereby 
increasing their growth and virulence8. Additionally, there is increasing awareness of the fact that the long-term, 
daily use of antiseptics can generate bacterial resistance due to the exposure to sub-lethal concentrations9. Some 
oral bacterial isolates can become resistant after being exposed to chlorhexidine. For instance, Porphyromonas 
gingivalis isolates increase their minimal inhibitory chlorhexidine concentration up to fourfold after exposure 
for 20 passages10. Moreover, Enterococcus faecalis increases its minimum inhibitory concentration (MIC) from 
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3 µg/mL to 11 µg/mL following 10 days of exposure to CHX11. Additionally, it is described that long-term use of 
antiseptics can also lead to increased MICs and thus resistance in vivo5,12,13.
This increase in MICs of antiseptics could potentially also result in resistance to antibiotics. Such 
cross-resistance phenotype is described for Klebsiella, Proteus and Staphylococcus species14–16. Acquired increased 
CHX resistance of Klebsiella pneumoniae was shown to result in cross-resistance to colistin, a last resort antibi-
otic17. Although a few studies already reported that some oral pathogens can become resistant to antiseptics after 
exposure, in general still little is known about this acquired antiseptic resistance/adapatation development and 
the concomitant changes at metabolic and protein levels.
It was hypothesized that repeated antiseptic exposure of the specific oral species used in this study would 
also result in increased antiseptic MICs and possibly in cross-resistance/adaptation to the other antiseptic and/
or commonly used antibiotics. Furthermore, it was expected that this repeated exposure to antiseptics would 
also have an impact on the bacterial cell membrane and proteome.The aim of this study was to determine the 
effects of repeated exposure to CHX and CPC on six bacterial oral pathogens in vitro, namely Aggregatibacter 
actinomycetemcomitans, Fusobacterium nucleatum, Porphyromonas gingivalis, Prevotella intermedia, Streptococcus 
mutans and Streptococcus sobrinus. For several of these species, no or only limited knowledge about the impact 
of antiseptic exposure is available in terms of (cross-)resistance/adaptation development and proteomic alter-
ations. In a first phase, this was done by monitoring the increase in antiseptic MICs of these pathogens during 
several passages in presence of antiseptics. Furthermore, given the mode of action of CHX and CPC, it was exam-
ined whether cross-adaptation to the other antiseptic and/or antibiotics commonly used in oral healthcare could 
occur. We hypothesized that (cross-)adaptation effects are accompanied by changes in cell surface properties and 
at protein level. The latter was investigated for the first time for these species under these specific conditions by 
mass spectrometry.
Results
Antiseptic adapatation development. The adaptation of oral pathogens to CPC and CHX was moni-
tored during exposure to these antiseptics for 10 consecutive passages. For each passage, bacteria were regrown in 
presence of one antiseptic concentration below the MIC observed for the previous passage. A tendency for adap-
tation, as observed by increasing MIC values, for all bacterial species and for both antiseptics was observed along 
the passages compared to the unexposed wild type strains (Fig. 1). At the 10th passage, the increase in CHX and 
CPC MIC values ranged between 1.3- and 2.5-fold for all the pathogens, except for P. intermedia that increased 
its MICs for CHX and CPC four-fold and for S. sobrinus that increased its MIC for CPC almost six-fold (Fig. 2, 
Supplementary Table S1). Based on these results, the 10-passages CHX- and CPC-exposed bacteria were further 
investigated in the following experiments and were referred to as CHX- or CPC-adapted bacteria.
Antiseptic and antibiotic cross-adaptation development. To verify if the antiseptic-adapted bac-
teria concomitantly show an increase in MIC of other antiseptics or antibiotics, the MIC values for the other 
antiseptic (CPC for the CXH-adapted bacteria and CHX for the CPC-adapted bacteria) and for four com-
monly used antibiotics (amoxicillin, azithromycin, metronidazole, tetracycline) were determined for wild type 
and antiseptic-adapted bacteria. Certain CHX- and CPC-adapted oral pathogens became concomitantly more 
adapted to CPC and CHX, respectively, when compared to the wild type bacteria (Fig. 3, Supplementary Table 
S2). CHX-adapted F. nucleatum, P. gingivalis, P. intermedia and S. sobrinus significantly increased their MICs for 
CPC 1.7-, 1.6-, 3.7- and 3-fold, respectively. In addition, CPC-adapted P. gingivalis, P. intermedia and S. sobrinus 
significantly increased their MICs for CHX 1.3-, 3.9- and 2.1-fold, respectively.
A similar cross-adaptation development to antibiotics was observed for some antiseptic-adapted species when 
compared to the wild type controls (Figs 4, 5, Supplementary Tables S3, S4). Increased MICs were observed for 
all antiseptic-adapted species for azithromycin, except for the antiseptic-adapted F. nucleatum, which showed a 
decreased MIC for this antibiotic. However, only for CHX-adapted P. gingivalis and S. sobrinus and CPC-adapted 
P. gingivalis and S. mutans, this increase could reach the level of significance. For the other antibiotics, a signifi-
cantly increased MIC for tetracycline was observed for the CHX-adapted S. sobrinus.
Reversibility of the antiseptic and antibiotic (cross-)adaptation effects. To elucidate if the 
increased MICs and bacterial (cross-)adaptation to antiseptics and antibiotics are (partially) reversible, CHX- 
and CPC-adapted bacteria were regrown in absence of antiseptics for 10 passages. MIC determinations showed 
that all CHX- and CPC-adapted species regrown in the absence of antiseptics, except for CHX-adapted P. gin-
givalis and CPC-adapted A. actinomycetemcomitans and S. mutans, had significantly increased antiseptic MICs 
compared to their wild type controls (Fig. 2, Supplementary Table S1). The level of antiseptic MICs remained in 
general similar between the antiseptic-adapted and the regrown antiseptic-adapted species with the exception 
of CHX-adapted P. intermedia and CPC-adapted A. actinomycetemcomitans, for which a significant decrease 
in MICs was noted when regrown in the absence of the antiseptics. Although both significantly decreased their 
MICs compared to the antiseptic-adapted species, CHX-adapted P. gingivalis still showed a significantly higher 
MIC compared to the wild type control, whereas the MIC of CPC-adapted A. actinomycetemcomitans dropped 
back to the same MIC value as the wild type control. In the case of CPC-adapted P. gingivalis, even a signifi-
cant increase in MIC was observed after regrowth in absence of the antiseptic. Therefore, antiseptic adaptation 
appeared to be at least partially conserved in most of the pathogens.
Possible loss of the cross-adaptation to antiseptics was evaluated identically. Most of the antiseptic-adapted 
bacteria that showed cross-adaptation to the other antiseptic maintained their cross-adaptation and thus their 
elevated MICs for this antiseptic (Fig. 3, Supplementary Table S2). However, CPC-adapted P. gingivalis and 
P. intermedia lost their cross-adaptation to CHX. Surprisingly, CHX-adapted S. mutans and CPC-adapted A. 
actinomycetemcomitans showed cross-adaptation to CPC and CHX, respectively, after regrowth in absence of 
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Figure 1. Monitoring of MIC values of CHX and CPC against six oral pathogens. Each oral pathogen was 
exposed to chlorhexidine (CHX) and cetylpyridinium chloride (CPC) during 10 consecutive passages. 
Minimum inhibitory concentrations (MICs) of both antiseptics against each pathogen were determined after 
each passage of exposure. Passage 0 corresponds to the unexposed wild type bacteria. Data are shown as average 
MIC values ± SD (n = 3).
Figure 2. Evaluation of antiseptic adaptation and its reversibility by determination of MIC values of CHX 
and CPC against six oral pathogens. Aa: A. actinomycetemcomitans; Fn: F. nucleatum; Pg: P. gingivalis; Pi: P. 
intermedia; MIC: Minimum Inhibitory Concentration; CHX: chlorhexidine; CPC: cetylpyridinium chloride; 
Control: unexposed wild type bacteria; Adaptation (10 P): bacteria exposed to CHX (a) or CPC (b) during 
10 passages; Reversibility (10 P): bacteria exposed to CHX (a) or CPC (b) during 10 passages and regrown in 
absence of antiseptics during 10 passages. Data are shown as average MIC values ± SD (n = 3). Statistically 
significantly higher MIC values when compared to the wild type control are marked with ‘*’ (P < 0.05), 
statistically significant differences between ‘Adaptation (10 P)’ and ‘Reversibility (10 P)’ are marked with ‘•’ 
(P < 0.05).
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Figure 3. Evaluation of antiseptic cross-adaptation and its reversibility by determination of MIC values of 
CHX and CPC against six oral pathogens. (a) MIC values of CHX against bacteria initially exposed to CPC. 
(b) MIC values of CPC against bacteria initially exposed to CHX. Aa: A. actinomycetemcomitans; Fn: F. 
nucleatum; Pg: P. gingivalis; Pi: P. intermedia; MIC: Minimum Inhibitory Concentration; CHX: chlorhexidine; 
CPC: cetylpyridinium chloride; Control: unexposed wild type bacteria; Adaptation (10 P): bacteria exposed to 
CPC (a) or CHX (b) during 10 passages; Reversibility (10 P): bacteria initially exposed to CPC (a) or CHX (b) 
during 10 passages and regrown in absence of antiseptics during 10 passages. Data are shown as average MIC 
values ± SD (n = 3). Statistically significantly higher MIC values when compared to the wild type control are 
marked with ‘*’ (P < 0.05), statistically significant differences between ‘Adaptation (10 P)’ and ‘Reversibility 
(10 P)’ are marked with ‘•’ (P < 0.05).
Figure 4. Evaluation of antibiotic cross-adaptation and its reversibility by MIC determination of four 
commonly used antibiotics against six oral pathogens exposed to CHX. (a) MIC values of amoxicillin against 
CHX-exposed bacteria. (b) MIC values of azithromycin against CHX-exposed bacteria. (c) MIC values of 
metronidazole against CHX-exposed bacteria. (d) MIC values of tetracycline against CHX-exposed bacteria. 
Aa: A. actinomycetemcomitans; Fn: F. nucleatum; Pg: P. gingivalis; Pi: P. intermedia; MIC: Minimum Inhibitory 
Concentration; CHX: chlorhexidine; Control: unexposed wild type bacteria; N.I.: not inhibited; Adaptation 
(10 P): bacteria exposed to CHX during 10 passages; Reversibility (10 P): bacteria exposed to CHX during 10 
passages and regrown in absence of antiseptics during 10 passages. Data are shown as average MIC values ± SD 
(n = 3). Statistically significantly higher MIC values when compared to the wild type control are marked with ‘*’ 
(P < 0.05). Statistically significantly different MIC values when comparing ‘Reversibility (10 P)’ to ‘Adaptation 
(10 P)’ are marked with ‘•’ (P < 0.05).
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antiseptics. Furthermore, in the case of CPC-adapted S. sobrinus and CHX-adapted F. nucleatum and S. sobrinus, 
their antiseptic MICs even increased further (P < 0.05) after regrowth in absence of antiseptics.
In a similar approach, the possible loss of the cross-adaptation for the CHX- and CPC-adapted species to 
antibiotics was evaluated (Figs 4, 5 and Supplementary Tables S3, S4). From the CHX-adapted bacteria, only S. 
sobrinus maintained its cross-adaptation to azithromycin and from the CPC-adapted bacteria, only P. gingivalis 
maintained and even significantly increased its elevated azithromycin MIC. Conversely, CHX-adapted P. gingi-
valis and S. sobrinus lost their increased azithromycin and tetracycline MICs, respectively. Also CPC-adapted S. 
mutans showed a decrease in its cross-adaptation to azithromycin. Similar to what was observed for antiseptic 
cross-adaptation reversibility, several antiseptic-adapted bacterial species actually increased their antibiotic MICs 
when regrown for 10 passages in the absence of the antiseptic. For instance, CHX-adapted F. nucleatum acquired a 
52.1-fold higher amoxicillin MIC, a 2.18-fold higher metronidazole MIC and a 2.72-fold higher tetracycline MIC 
after 10 passages without antiseptics (Fig. 4, Supplementary Table S3), although the wild type species exposed 
to CHX during 10 passages did not show cross-adaptation to amoxicillin. Similar observations of acquisition 
of antibiotic cross-adaptation were made for CHX-adapted P. gingivalis (amoxicillin, 4-fold increase in MIC), 
P. intermedia (metronidazole, 2.21-fold increase in MIC), S. mutans (amoxicillin, 1.83-fold increase in MIC), S. 
sobrinus (amoxicillin, 3.48-fold increase in MIC) and for CPC-adapted S. sobrinus (amoxicillin and azithromycin, 
4.23-fold and 1.32-fold increase in MIC, respectively) repassaged in absence of antiseptics.
Changes in cell surface hydrophobicity. In order to verify if changes in cell-surface properties of the oral 
pathogens could be one of the possible underlying mechanisms explaining the observed effects, the cell-surface 
hydrophobicity was determined. All antiseptic-adapted species had a higher cell surface hydrophobicity, com-
pared to their wild type controls (Fig. 6a). This increased cell surface hydrophobicity reached a level of statistical 
significance for CHX-adapted F. nucleatum, P. gingivalis, P. intermedia and S. mutans and CPC-adapted A. actin-
omycetemcomitans, F. nucleatum, P. gingivalis and S. mutans. Cell surface hydrophobicity of antiseptic-adapted 
species regrown in absence of antiseptics for 10 passages was determined as well. For these strains as well, all 
Figure 5. Evaluation of antibiotic cross-adaptation and its reversibility by MIC determination of four 
commonly used antibiotics against six oral pathogens exposed to CPC. (a) MIC values of amoxicillin against 
CPC-exposed bacteria. (b) MIC values of azithromycin against CPC-exposed bacteria. (c) MIC values of 
metronidazole against CPC-exposed bacteria. (d) MIC values of tetracycline against CPC-exposed bacteria. 
Aa: A. actinomycetemcomitans; Fn: F. nucleatum; Pg: P. gingivalis; Pi: P. intermedia; MIC: Minimum Inhibitory 
Concentration; CPC: cetylpyridinium chloride; Control: unexposed wild type bacteria; N.I.: not inhibited; 
Adaptation (10 P): bacteria exposed to CPC during 10 passages; Reversibility (10 P): bacteria exposed to CPC 
during 10 passages and regrown in absence of antiseptics during 10 passages. Data are shown as average MIC 
values ± SD (n = 3). Statistically significantly higher MIC values when compared to the wild type control are 
marked with ‘*’ (P < 0.05). Statistically significantly different MIC values when comparing ‘Reversibility (10 P)’ 
to ‘Adaptation (10 P)’ are marked with ‘•’ (P < 0.05).
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bacteria had a higher cell surface hydrophobicity compared to their wild type controls, except for S. sobrinus, 
which showed similar values (Fig. 6b). These increases were statistically significant for CHX-adapted A. actin-
omycetemcomitans, F. nucleatum, P. gingivalis, P. intermedia and S. mutans regrown in absence of CHX and for 
CPC-adapted A. actinomycetemcomitans, F. nucleatum, P. gingivalis and S. mutans regrown in absence of CPC.
proteomic analysis of antiseptic-adapted species. Since the periodontopathogens acquired the high-
est MIC levels and showed the largest changes in cell-surface hydrophobicity, proteomic analysis was performed 
for the CHX- and CPC-adapted periodontopathogens and their wild type controls. For all antiseptic-adapted 
periodontal species, clear alterations in a wide range of bacterial metabolic and behavioral pathways following the 
exposure to antiseptics were shown (Fig. 7, Supplementary Tables S5–S8). These changes at protein level were most 
pronounced in CHX- and CPC-adapted P. gingivalis, both in terms of upregulation and unique presence of certain 
proteins compared to the wild type control. In contrast, P. intermedia showed the least changes at protein level 
when considering the numbers of upregulated or unique proteins together. Additionally, differences in the amount 
of upregulated or unique proteins were observed depending on the type of antiseptic that was used. Exposure to 
CPC generally induced higher numbers of upregulated or unique proteins than exposure to CHX. When looking 
at functions associated with the uniquely present or upregulated proteins, they appeared to be mainly involved in 
bacterial metabolism, membrane and cell wall modifications, membrane transport, bacterial virulence and resist-
ance to oxidative stress (Figs 7, 8, Supplementary Tables S5–S8). It is noteworthy that there were also a consider-
able number of proteins downregulated in the antiseptic-adapted species, or only detected in the unexposed wild 
type species. An overview of these particular proteins can be found in Supplementary Table S9.
Figure 6. Cell surface hydrophobicity analysis of wild type and antiseptic-adapted oral pathogens. (a) Cell 
surface hydrophobicity of antiseptic-adapted bacteria. Wild type control: unexposed wild type bacteria; CHX-
adapted (10 P): bacteria adapted to chlorhexidine (CHX) after exposure during 10 passages; CPC-adapted 
(10 P): bacteria adapted to cetylpyridinium chloride (CPC) after exposure during 10 passages. (b) Cell surface 
hydrophobicity of antiseptic-adapted bacteria regrown in absence of antiseptics. Wild type control: unexposed 
wild type bacteria; CHX reversibility (10 P): bacteria initially exposed to CHX during 10 passages and regrown 
in absence of antiseptics during 10 passages; CPC reversibility (10 P): bacteria initially exposed to CHX 
during 10 passages and regrown in absence of antiseptics during 10 passages. Aa: A. actinomycetemcomitans, 
Fn: F. nucleatum, Pg: P. gingivalis, Pi: P. intermedia. Cell surface hydrophobicity is represented as the average 
percentage of adherence to N-hexadecane ± SD (n = 3). Statistically significantly different values when 
compared to the wild type control are marked with an ‘*’ (P < 0.05).
Figure 7. Overview of the proteomic analysis of antiseptic-adapted species in terms of unique or upregulated 
proteins. Aa: A. actinomycetemcomitans; Fn: F. nucleatum; Pg: P. gingivalis; Pi: P. intermedia; CHX: 
chlorhexidine; CPC: cetylpyridinium chloride; CHX-adapted (10 P): bacteria exposed to CHX during 10 
passages; CPC-adapted (10 P): bacteria exposed to CPC during 10 passages. Unique proteins were not detected 
in the wild type species; upregulated proteins were significantly increased compared to the wild type species  
(*, P < 0.05). Colored squares represent the main functional domains associated with the detected proteins.
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Discussion
This in vitro study showed that oral pathogens can develop adaptation to CHX and CPC upon exposure to 
sub-inhibitory concentrations of these antiseptics, which lead to statistically significantly increased MICs. 
Concomitantly, the occurrence of cross-adaptation to other antiseptics (CPC or CHX) and antibiotics was shown. 
These increased MICs are (partially) maintained after discontinuing the exposure to the antiseptic. Additionally, 
it was shown that wild type and antiseptic-adapted bacterial strains grown under identical conditions differ in cell 
surface hydrophobicity and in unique and/or upregulated expression of proteins involved in bacterial metabo-
lism, membrane and cell wall modifications, membrane transport, bacterial virulence and resistance to oxidative 
stress. As far as we know, this study is the first one to examine the impact of antiseptic exposure in vitro on these 
six different species at the same time and to investigate the accompanying effects at protein level through mass 
spectrometry analysis.
The exposure of oral pathogens to CHX or CPC resulted in a progressive increase in the antiseptic MICs over 
the different passages, with the 10th passage generally yielding the highest MIC levels. All pathogens increased 
their MICs with factors ranging from 1.3 to 5.5, depending on the bacterial species and the antiseptic. These data 
are in line with other studies, where some of these species also showed increases in MICs for CHX in the same 
order of magnitude. For instance, some clinical oral isolates of P. gingivalis increased their MIC values for CHX up 
to fourfold after 20 passages in the presence of sub-inhibitory concentrations of CHX10. In addition, the oral path-
ogen Enterococcus faecalis was also found to increase its MICs for CHX up to 3.6-fold after 10 passages, but not 
for CPC11. Also Streptococcus sanguinis strains have been shown to increase their CHX MICs 8-fold18. Although 
two recent studies did not show a significant increase in S. mutans CHX and/or CPC MICs after repeated expo-
sure10,11, the current data shows the opposite. Since the test conditions in one of the two latter studies were quite 
similar to those described in this study, it therefore can be hypothesized that antiseptic resistance/adaptation 
development is not only species-dependent, but also strain-dependent. Indeed, strain differences in antiseptic 
resistance development have been shown for Staphylococcus aureus and P. gingivalis strains10,19. The observed 
in vitro CHX adaptation for A. actinomycetemcomitans, F. nucleatum and P. intermedia and CPC adaptation for 
the oral pathogens tested in this study has never been reported yet and/or deeply studied. However, in regards 
to the latter, Pseudomonas stutzeri, Pseudomonas aeruginosa and Campylobacter jejuni have shown adaptation to 
CPC20,21. The clinical relevance of these in vitro data is unclear, since there is a general conception that CHX and 
CPC do not induce resistance in vivo, and are therefore safe13,22–27. However, the studies on which these concep-
tions are based are not always properly designed, are not including the bacterial species of interest, are showing an 
increase in MICs or are even lacking in the case of CPC. Schiott and coworkers (1976) did show increased CHX 
MICs in the total salivary flora and for selected salivary streptococci after 17 and 23 months of CHX use28. Similar 
observations were made by Emilson and Fornell (1976) following a 1-year CHX treatment12. Also, Maynard 
and coworkers (1993) reported an increase in MIC for anaerobic supragingival plaque bacteria for CHX during 
a 6-month trial13. However, a triple application of a CHX gel or varnish in a 1-week period did not change the 
CHX MIC of salivary S. mutans and S. sobrinus in a period of 4 to 28 weeks after application29. Unfortunately, 
none of these studies looked at specific bacterial species which we nowadays link with periodontal diseases. Our 
Figure 8. General overview of the main proteomic alterations in antiseptic-adapted oral pathogens. Proteomic 
analysis of antiseptic-adapted oral pathogens by means of mass spectrometry revealed alterations in protein 
expression compared to the unexposed wild type species. When looking at the functions of the uniquely present 
or upregulated proteins, they appeared to be mainly involved in bacterial metabolism, membrane transport, 
cell wall modifications, bacterial virulence and oxidative stress protection. More specifically, exposure of oral 
pathogens to antiseptics resulted in proteomic changes that can possibly be associated with an altered metabolic 
homeostasis (increased energy, amino acid, nucleotide and other metabolisms), increased efflux transport, 
changes in bacterial cell wall, increased bacterial pathogenicity and virulence, and changes in pathways involved 
in protection against oxidative stress to DNA, proteins and lipids. Uniquely present proteins were not detected 
in the wild type species; upregulated proteins were significantly increased compared to the wild type species 
A more detailed overview of all proteins and more examples can be found in Supplementary Tables S5–S9. 
Aa: A. actinomycetemcomitans; Fn: F. nucelatum; Pg: P. gingivalis; Pi: P. intermedia; CHX: chlorhexidine; CPC: 
cetylpyridinium chloride. CHX-adapted species: bacteria exposed to CHX during 10 passages. CPC-adapted 
species: bacteria exposed to CPC during 10 passages.
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in vitro data support these rudimentary clinical findings. However, it should be taken into account that there are 
distinct differences between our in vitro study and the real-life situation in the daily practice. Firstly, the exposure 
time used in the current study (i.e. 24 h) is different from usual exposure times in real-life situations (i.e. 30 s - 
1 min, 3 times a day). Following on that, the current study looked at which changes occurred after 10 passages 
of exposure. This in contrast with the real-life situation, where people often use mouth rinses on a daily basis for 
weeks, months or even years. Secondly, there is a difference in terms of antiseptic concentrations. In our study, the 
antiseptic concentrations used in the MIC experiments ranged from 0.1–21 µg/mL, yielding MICs in the ranges 
of 3–10 µg/mL (CHX) and 3–13.7 µg/mL (CPC). This is considerably different from antiseptic concentrations 
commonly found in commercial mouth rinses, for instance 0.12–0.2% CHX (~1200–2000 µg/mL) or 0.07% CPC 
(~700 µg/mL). Lastly, also other factors could play important roles in vivo, such as dilution and clearance of anti-
septics by the saliva.
In order to determine the possible reversibility of the induced antiseptic adaptation, the pathogens were repas-
saged in absence of CHX or CPC. The results showed that the induced adaptation was usually at least partially 
retained in absence of the antiseptic. S. sanguinis, P. stutzeri and P. aeruginosa show a similar (partial) behavior for 
CHX and CPC18,21. The in vitro data are in contrast with the findings of Schiott et al. (1976) who showed a reversal 
to control MIC values for CHX after 3 to 6 months28. However, in this study, no differentiation was made between 
different bacterial species and the students included in this study did not suffer from periodontal diseases or tooth 
decay. Therefore, one cannot be sure that after discontinuing an antiseptic therapy or during a prolonged antisep-
tic therapy, increased MIC levels will return to pre-treatment levels, or will not keep rising.
Since the early 2000’s, several studies have already shown that frequent usage of antiseptics can be accompa-
nied by increased MICs and even resistance to antibiotics16,30,31. Repeated exposure of human bacterial pathogens 
to biocides can indeed act as a driver of antibiotic resistance development32. Our data are in line with this con-
cept. Increased antibiotic MIC values were recorded for the CHX- or CPC-adapted strains albeit these increases 
were at maximum twofold. Interestingly, for some antiseptic-adapted strains that were cultured for 10 passages 
without the antiseptic, MICs for the tested antibiotics even increased more. A similar observation was made by 
Tattawasart and coworkers (1999) for Pseudomonas species21. At the moment it is unclear what might explain 
this increase in MICs. In general, the increased MIC values were still below the achievable salivary concentrations 
of the respective antibiotics33. However, the antiseptic-induced increase in A. actinomycetemcomitans MICs for 
amoxicillin brought its MIC value above the salivary amoxicillin concentration of 0.7 µg/mL.
Since CHX and CPC are both cationic biocides, they share their main mode of action. Both act as posi-
tively charged surfactants that bind to the negatively charged phospholipids of the bacterial cell membranes, 
which eventually leads to rupture, cytoplasmic leakage and cell death15,34,35. Therefore, it was hypothesized that 
antiseptic-adapted bacteria could possibly become cross-adapted to the other antiseptic. Three out of six of both 
the CHX- and CPC-adapted species showed such cross-adaptation. In line with the mode of action of both anti-
septics, one could expect that the antiseptic-adapted bacteria displayed changes in their cell membranes com-
pared to the unexposed wild type controls. For both the CHX- and CPC-adapted pathogens, four out of the six 
species significantly increased their surface hydrophobicity. For the same antiseptic-adapted pathogens regrown 
in absence of antiseptics, this was the case for five (CHX) and four (CPC) out of the six species. This can possibly 
be an underlying mechanism of the observed adaptation in the pathogens. It is known that biocide resistance 
often occurs through changes in membrane permeability and properties21,36. However, as not all six CHX- and 
CPC-adapted species showed an increase in surface hydrophobicity, and since in another study E. faecalis exposed 
to CHX and CPC only became resistant to CHX, but increased its hydrophobicity in both cases of exposure11, one 
can expect that other mechanisms play a role. In addition, it is noteworthy that 4 out of the 6 bacterial species used 
in this study are Gram-negatives (A. actinomycetemcomitans, F. nucleatum, P. gingivalis, P. intermedia), whereas 
the other 2 species (S. mutans and S. sobrinus) are Gram-positives. Given the differences in membrane structure 
between both types of bacteria, such as the absence of an outer membrane for Gram-positives, one could maybe 
anticipate major differences in terms of hydrophobicity changes. However, this was not the case, as both the 
Gram-negative and Gram-positive species increased their hydrophobicity. As described above, both antiseptics 
act by binding to negatively charged components. This is associated with the cytoplasmic membrane itself (pres-
ent in both Gram-positives and Gram-negatives), polysaccharide elements and teichoic acids (Gram-positives) 
and lipopolysaccharides (outer membrane of Gram-negatives)37. Compared to the antiseptic-adapted species, the 
majority of antiseptic-adapted species regrown in absence of antiseptics showed similar trends (with respect to 
their observed changes in MIC values) in cell surface hydrophobicity changes compared to their wild type con-
trols. However, CHX-adapted A. actinomycetemcomitans regrown in absence of CHX, which had a similar CHX 
MIC compared to the same antiseptic-adapted species, significantly increased its cell surface hydrophobicity 
whereas this was not the case for CHX-adapted A. actinomycetemcomitans. Similarly, CPC-adapted P. gingivalis 
regrown in absence of CPC, which had a higher CPC MIC compared to the same antiseptic-adapted species, 
had a lower cell surface hydrophobicity compared to CPC-adapted P. gingivalis. Nevertheless, there was still a 
statistically significant increase in cell surface hydrophobicity compared to the wild type control in both cases. All 
this supports the hypothesis that changes in cell surface hydrophobicity are possibly (in part) one of the under-
lying mechanisms of the antiseptic adaptation observations made, or at least one of their accompanying effects. 
However, based on these results, one cannot simply draw a direct causal relationship between changes in cell 
surface hydrophobicity and the observed adaptation effects.
To investigate other potential adaptation mechanisms and (accompanying) effects, the protein fractions of 
CHX- and CPC-adapted periodontal bacteria, as well as those of the corresponding unexposed wild type bacte-
ria, were analyzed by means of mass spectrophotometry. The analysis of the proteomes of the antiseptic-adapted 
species revealed alterations in specific survival and adaptive mechanisms because of the exposure to antiseptics. 
The proteomics data showed that antiseptic-adapted bacteria changed their metabolic profiles for instance by 
the upregulation of proteins involved in energy metabolism and more specifically in glycolysis, gluconeogenesis, 
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citric acid cycle and lysine degradation pathways. Additionally, levels of proteins involved in amino acid, nucle-
otide and inorganic ion metabolisms were also increased. Similar changes have already been described in 
multi-resistant Staphylococcus aureus and Enterococcus species resistant to important antibiotics such as methi-
cillin, vancomycin, linezolid, and daptomycin38. Proteomic analyses of these antibiotic-resistant species showed 
an increase in the presence of glyceraldehyde-3-phosphate dehydrogenase, 2,3-bisphosphoglycerate-dependent 
phosphoglycerate mutase, alcohol dehydrogenase and succinyl-CoA synthetase, which all were found to be also 
upregulated in the antiseptic-adapted periodontal species39–42. This might indicate that certain bacterial meta-
bolic adaptations are conserved in response to exposure to antiseptics as well as to antibiotics, suggesting that 
these proteins could be specific targets in the prevention of bacterial resistance. In addition, antiseptic-adapted 
periodontal species showed proteomic differences possibly related to defense mechanisms against the antisep-
tics. For instance, we observed the upregulation and/or unique presence of proteins associated with several 
types of ABC transporters, which have already been related to the efflux of antibiotics in several multi-resistant 
species43. Furthermore, CHX-adapted P. gingivalis significantly upregulated its RND transporter MFP subu-
nit. Transcriptional upregulation of efflux transporters belonging to the resistance-nodulation-division (RND) 
family of efflux transporters is something that was also observed in CHX-exposed Burkholderia cenocepacia, 
a Gram-negative bacterium involved in cystic fibrosis pathogenesis for which highly CHX-resistant strains 
have been described44,45. Additionally, other underlying mechanisms could possibly be found in the upregu-
lation of several proteins related to membrane and cell wall modifications that are, more specifically, associ-
ated with increased synthesis of peptidoglycan and lysine, cell envelop biogenesis and β-oxidation of fatty acids. 
Similar alterations in cell wall architecture have been reported in non-oral bacteria resistant to antimicrobial 
compounds38,46,47.
Furthermore, the proteomic analysis of the antiseptic-adapted species revealed the upregulation of proteins 
involved in resistance to oxidative stress damage to proteins, lipids and DNA, caused by the use of antiseptics and 
antibiotics48. Resistance to oxidative stress is often also related to bacterial resistance to antibiotics49. These pro-
teins have also been found to be upregulated in non-oral species resistant to multiple antibiotics38,50.
The exposure to CHX and CPC also induced the upregulation and the unique presence of virulence-related 
proteins in periodontal pathogens, suggesting that antiseptics can trigger an increase in pathogenicity and viru-
lence potential of these pathogens. For instance, gingipain proteins (RgpA and Kgp), which are arginine or lysine 
specific cysteine proteinases produced by P. gingivalis, were only detected in CHX- and CPC-adapted P. gingivalis. 
These proteins are involved in hemolysis and iron uptake, degradation of host tissues, deregulation of the immune 
response and bacterial co-aggregation51. Other virulence proteins such as hemagglutinin A, hemolysin secretion 
protein D and tRNA(Glu)-specific nuclease (WapA), which are related to hemagglutination, hemolysis and toxin 
activity, were also either upregulated or uniquely present in the antiseptic-adapted species. In contrast with this 
effect, a study on the exposure of S. aureus to sub-lethal vancomycin concentrations found decreased amounts 
of most proteins with a virulence-related function52. However, in another study, the proteomic analysis of 
methicillin-resistant S. aureus revealed the unique presence of two virulence-related proteins, fibrinogen-binding 
protein and bone sialoprotein-binding protein, which are involved in attachment to the host tissue and play a key 
role in the initiation of endovascular infections and prosthetic-device infections41.
Future studies should further elucidate the underlying mechanisms and look at clinically more relevant situa-
tions. Firstly, sequencing of the different types of bacteria obtained throughout this study might be interesting to 
reveal possible genomic changes that in turn could be linked to the observed effects and changes at protein level. 
Given the unexpected results in the reversibility experiments, proteomic analysis of the bacteria obtained in these 
experiments could shed a new light on this complex phenomenon. Furthermore, different strains and/or clinical 
isolates of the bacterial species used in this study could be subjected to similar experiments, in combination with 
the use of antiseptic concentrations and exposure times/frequencies mimicking more real-life situations. This 
could provide more insights into the clinical significance and relevance of the obtained results.
In conclusion, six oral pathogens were found to become adapted to antiseptics after repeated exposure to CHX 
and CPC. This antiseptic adaptation was in general at least partially conserved after regrowth in absence of anti-
septics. Furthermore, some of the antiseptic-adapted species also showed cross-adaptation to antibiotics and the 
other antiseptic. The possible underlying mechanisms are changes in cell surface hydrophobicity and alterations 
at the proteomic level. Moreover, most antiseptic-adapted species increased their cell surface hydrophobicity and 
(over)expressed proteins with functions that can be related to the observed (cross-)adaptation effects.
Materials and Methods
Bacterial species, media and antiseptics. Prevotella intermedia ATCC 25611, Porphyromonas gin-
givalis ATCC 33277, Fusobacterium nucleatum DSM 20482, Streptococcus mutans ATCC 20523, Streptococcus 
sobrinus ATCC 20742 and Aggregatibacter actinomycetemcomitans ATCC 43718 were maintained on blood agar 
(Blood agar Base I, Oxoid, Basingstoke, UK) supplemented with hemin (Sigma-Aldrich, St. Louis, MO, USA) 
(5.0 mg/mL), menadione (Calbiochem-Novabiochem, La Jolla, USA) (1.0 mg/mL) and 5% sterile horse blood 
(E&O Laboratories, Bonnybridge, Scotland). Broth cultures were prepared in Brain Hearth Infusion (BHI) broth 
(Difco, Detroit, USA). Minimum Inhibitory Concentration (MIC) experiments were performed in Brain Hearth 
Infusion (BHI) containing chlorhexidine (CHX) and cetylpyridinium chloride (CPC) (Sigma-Aldrich, St. Louis, 
USA). Development of adapted species was performed in BHI or on blood plates supplemented with CHX or 
CPC, depending on the bacterial strain. For all experiments, bacteria were cultured under aerobic (5% CO2) or 
anaerobic (80% N2, 10% H2 and 10% CO2) conditions. Optical densities were measured at 600 nm (OD600) by 
spectrophotometry using a GeneQuant spectrophotometer (Biochrom Ltd., Cambridge, United Kingdom).
Antiseptic adaptation development. Overnight cultures of A. actinomycetemcomitans, F. nucleatum, S. 
mutans and S. sobrinus were adjusted to 107 CFU/mL (OD600 ~ 0.5). CHX or CPC was dissolved in BHI at final 
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concentrations ranging from 0.1 to 21 µg/mL and resulting solutions were added to a 96-well plate together with 
the adjusted bacterial cultures (final OD600 ~ 0.250), followed by a 24-h incubation at 37 °C under anaerobic con-
ditions. MICs were determined by visual examination as well as by optical measurement at 600 nm by means of a 
Multiskan Ascent 96-well plate reader (Thermo Fisher Scientific, Waltham, USA). The MIC value was defined as 
the minimum antiseptic concentration at which no bacterial growth could be observed.
Bacterial solutions from the last well in which bacterial growth could be detected (i.e. containing CHX or CPC 
at one concentration lower than the MIC) were added to 10 mL BHI supplemented with the same concentration 
of antiseptic and incubated for 24 h at 37 °C. Afterwards, bacterial cultures were centrifuged and resulting pellets 
washed with fresh BHI medium to remove residual antiseptic solution. Pellets were subsequently resuspended in 
fresh BHI medium, bacterial solutions were adjusted to 107 CFU/mL (OD600 ~ 0.5) and MIC determination was 
repeated as described before. This procedure was done for 10 consecutive passages.
A modified protocol was used for checking the increase in adaptation of P. intermedia and P. gingivalis, since 
their growth was fastidious and slow in the liquid cultures between the MIC determinations. Therefore, increas-
ing the adaptation of P. intermedia and P. gingivalis was performed on agar plates containing a radial gradient of 
CHX or CPC created by an Autoplate® 4000 spiral plater (Spiral Biotech Inc., Norwood, USA). The antiseptic 
MIC value observed in the 96-well plate was used as the highest concentration in the gradient. Distribution of the 
antiseptics in an Archimedes spiral from the center to the edge established a ~1000-fold concentration gradient 
where the higher concentrations were located towards the center and the lower concentrations towards the edge. 
After 48 h of incubation, P. intermedia and P. gingivalis colonies situated in the area with the highest antiseptic 
concentration were taken, resuspended in BHI and adjusted to 107 CFU/mL (OD600 ~ 0.5). MICs determination 
of P. intermedia and P. gingivalis were performed as described earlier for the other oral pathogens. Samples of the 
10th passage from all oral species were stored at −80 °C for further use. All experiments were repeated on three 
different days.
Antiseptic and antibiotic cross-adaptation development. To examine cross-adaptation develop-
ment to other antiseptics, a MIC analysis was performed for wild type (no previous exposure to CPC or CHX), 
CPC- and CHX-adapted species for CHX and CPC respectively, as described above. The MIC of CPC was deter-
mined for the wild type and CHX-adapted species and the MIC of CHX was determined for the wild type and 
CPC-adapted species.
In addition, cross-resistance development of CHX- and CPC-adapted species to four commonly used anti-
biotics (amoxicillin, azithromycin, metronidazole and tetracycline) was examined by means of ETEST® strips 
(BioMérieux, Brussels, Belgium). Overnight cultures of wild type, CHX- and CPC-adapted bacterial species were 
adjusted to 107 CFU/mL (OD600 ~ 0.250) and inoculated on blood agar plates. ETEST® strips containing a con-
centration gradient of amoxicillin, azithromycin, metronidazole or tetracycline were placed on the blood agar 
plates and incubated under anaerobic conditions at 37 °C for 10 days. A calibrated (by means of a ruler) and 
standardized (fixed distance between photo camera and agar plate) photograph was taken from each agar plate. 
MIC values were determined visually as the antibiotic concentration at which the edge of the inhibition ellipse 
intersected with the sides of the antibiotic strip. When the MIC was lower than the lowest concentration present 
in the gradient, the value was estimated by extrapolation after measuring the distance (in mm) between the edge 
of the inhibition ellipse and the lowest concentration on the ETEST® strip using ImageJ (Imaging processing and 
Analysis in Java) software. All experiments were repeated on three different days.
Reversibility of the (cross-)adaptation development. In order to verify if the induced adaptation and 
cross-adaptation development was reversible, adapted species were grown in absence of antiseptics on agar plates 
without antiseptics for 10 passages. Wild type controls were handled in the same way. Bacterial suspensions 
were subsequently adjusted to 107 CFU/mL (OD600 ~ 0.5). MICs determinations were performed to re-evaluate 
the antiseptic adaptation and the antiseptic cross-adaptation, whereas ETEST® strips were used to re-determine 
the cross-adaptation to antibiotics. MIC and ETEST® experiments were performed as described previously. All 
experiments were repeated on three different days.
Analysis of cell-surface hydrophobicity. Cell-surface hydrophobicity of wild type, CHX-adapted and 
CPC-adapted bacteria was measured by microbial adherence to n-hexadecane53. Bacterial suspensions were 
washed twice and re-suspended in phosphate-urea-magnesium sulfate buffer (100 mM sodium phosphate buffer, 
pH 7.1, 30 mM urea, 0.8 mM MgSO4) to an initial optical density at 550 nm (OD550) of 0.55–0.60. Four mL of 
bacterial suspension was mixed vigorously with 0.5 mL of n-hexadecane (Sigma-Aldrich, St. Louis, USA) for 30 s, 
and left at room temperature for 10 min. The OD550 of the lower aqueous phase was measured and hydropho-
bicity was represented as the percentage of adherence (% AD) to the hydrocarbon. The latter was calculated as: 
[% AD = (1 − A/I) × 100], where I equals the OD550 of the initial cell suspension and A equals the OD550 of the 
aqueous phase54. All experiments were repeated on three different days.
proteomic analysis. Protein purification. 20 mL of overnight culture of the wild type, CHX-adapted 
and CPC-adapted strains was centrifuged (30 min at 4000 × g) and washed with physiological saline solu-
tion. Next, bacterial pellets were washed with 10 mL buffer A (50 mM HEPES, pH 7.5, 300 mM NaCl, 5 mM 
β-mercapto-ethanol, 1 mM EDTA) and centrifuged at 4 °C (30 min at 4000 × g). Supernatant was discarded and 
20 mL of buffer B (buffer A supplemented with 1 µg/mL leupeptin, 0.1 mg/mL AEBSF (4-(2-aminoethyl)ben-
zenesulfonyl fluoride hydrochloride)) was added to the bacterial pellet. Breaking of the cells was done by means 
of a Glen Creston Cell Homogenizer (pressure set to 20000–25000 psi) and suspensions were also sonicated 
(Branson digital sonifier 50/60 HZ) on ice during an alternating 2 min cycle (15 s pulses at 50% power, 30 s pauses 
on ice, until completion of 2 min of total sonication time)55.
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Mass spectrometry experiments. For the mass spectrometry experiments, dithiothreitol (DTT) solution (final 
concentration 0.020 M) was added to the purified proteins and the mixture was incubated at room temperature 
for 15 min. Subsequently, iodoacetamide (IAA) was added to the solution (final concentration 0.050 M) followed 
by a 30-min incubation in the dark. Next, ammonium bicarbonate (ABC) (final concentration 0.11 M) was added 
to the samples (starting material 20 µg) together with trypsin (0.2 µg trypsin per 20 µg protein). Trypsin digestion 
was allowed to take place during at least 16 h at 37 °C to ensure complete proteolysis. Afterwards, resulting pep-
tides were cleaned using C18 spin Columns (Thermo Fisher Scientific, Waltham, USA). Cleaned peptides were 
subsequently dried by Speedvac. Finally, the dried peptides were diluted in 10 µL 5% ammonium bicarbonate/
acetonitrile (ACN) + 0.1% formic acid (FA) according to the manufacturer’s instructions for injection in the mass 
spectrometer (Q Exactive Orbitrap mass spectrometer, Thermo Fisher Scientific, Waltham, USA)55.
Analysis of mass spectrometry data. The peptide samples (5 µL of each sample) were digested and subsequently 
injected for UPLC separation by an Ultimate 3000 UPLC System (Dionex, Thermo Fisher Scientific, Waltham, 
USA), using an Acclaim PepMap100 pre-column (C18 3µm-100 Å, Thermo Fisher Scientific, Waltham, USA) 
and a C18 PepMap RSLC (2 μm, 50 μm-15 cm, Thermo Fisher Scientific, Waltham, USA) using a linear gradient 
(300 μL/min) of 0–4% buffer B (80% ACN, 0.08% FA) for 3 min, 4–10% B for 12 min, 10–35% for 20 min, 35–65% 
for 5 min, 65–95% for 1 min, 95% for 10 min, 95–5% for 1 min, and 5% for 10 min. The operational settings of 
the mass spectrometer and data acquisition procedure were identical to those described earlier by Khodaparast 
et al.55. With the purpose of identification, all raw data were converted into mgf.files using Proteome Discover 
version 1.4 (Thermo Fisher Scientific, Waltham, USA) and processed with MASCOT version 2.2.06 (Matrix 
Science Ltd, London, UK) against the Uniprot A. actinomycetemcomitans, F. nucleatum, P. gingivalis or P. inter-
media database. The parameters used to search with MASCOT are described elsewhere55. MASCOT results were 
imported to Scaffold (version 3.6.3). The parameters used in Scaffold for protein identification were retaining 
proteins with 99% confidence and containing at least two identified peptides with a confidence level of 95%.
statistical analysis. For each component and species apart, a weighted linear mixed model with run as 
random factor and treatment and time as crossed fixed factors was fit. Weights were inversely proportional to the 
variance of each combination of the fixed factors. Normality of the residuals was assessed by means of a normal 
quantile plot. The comparison between treatments was performed between treatments for every time separately 
and a correction for simultaneous hypothesis testing according to Sidak was performed.
Data Availability
The authors declare that all data supporting the findings of this study are available within the paper and its sup-
plementary information files.
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